Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
  • USA - English


News provided by

Emergent Technologies, Inc.

Jul 25, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX


This technology would make it possible for the people who care most, to donate their organ to those they love most, but with whom they do not match for tissue type.

Post this

Austin, Texas (PRWEB) July 25, 2013 -- Pure Transplant Solutions, LLC (PTS) a biotechnology start-up company looking to revolutionize the future of transplantation medicine, has launched a campaign on the crowdfunding site, Indiegogo.com, to raise awareness and development funds of $100,000 in 45 days for its proprietary, selective Antibody Removal Column (the ARCTM). The ARC is a medical device that filters and selectively removes harmful antibodies from an organ recipient’s blood to allow an organ of a non-matched donor to be transplanted into the recipient, without the usual risk of organ rejection. The name of the PTS Indiegogo campaign is "Any Organ Any Body".

According to the Organ Procurement and Transplantation Network (OPTN), it is estimated that over 215,000 Americans die yearly from diseases that are treatable by transplant. Each day, an average of 79 people receive a transplant, but on that same day, an average of 18 people die waiting for one. The length of time a person has to wait for a transplant depends on many things but is primarily determined by the degree of matching between a person and a donor.

More than 80% of US transplant candidates are waiting for kidneys. One third of patients waiting for a kidney are considered to be “highly sensitized” meaning they have high levels of harmful antibodies and may never be matched with a donor no matter how long they are on the waiting list.

The ARC directly addresses this issue by allowing living donors to donate a kidney. “This technology would make it possible for the people who care most, to donate their organ to those they love most, but with whom they do not match for tissue type; with less reliance on the organ banks,” said Dr. Gina Lento, PTS Vice President. “The ARC not only decreases the risk of organ rejection, but is also much safer than existing treatments since it doesn’t strip the blood of all antibodies and proteins, only those that don’t match with a donor.”

The ARC can be used to treat any kind of solid organ or bone marrow transplant recipient, but as with most innovations in transplant medicine, new treatments are tried in kidney transplantation first since kidney transplants are the most frequent and have the highest survival rates.

With the ARC technology, organ transplantation will become an option for those patients who have been unable to find a donor match based on their highly sensitized condition. Long-term survival rates and quality of life of patients will increase as the frequency of organ rejection episodes decrease. The ARC will also decrease the time patients have to wait for an organ, and it will significantly impact the donor organ pool by making organs available regardless of tissue match.

“There are hundreds of thousand of people globally that could benefit from the ARC technology and we believe a crowdfunding campaign is the best way to get the word out about its potential,” said Dr. William Hildebrand, PTS Founder and Chief Scientist.

Indiegogo is the world's largest self-serve open-funding platform offering rewards in exchange for contributions. For as little as $5, a pledge can be made to help advance the ARC technology and become a part of transplantation history. Other perks include a limited edition “Any Organ Any Body” t-shirt and an autographed copy of The Climb of My Life the true story of world-renowned mountain climber and heart transplant recipient, Kelly Perkins. A larger contribution secures two tickets to an exclusive event in Austin, TX where contributors will meet the scientific team, enjoy food, drink and live music by nine-time Grammy winner and lead singer of Asleep at the Wheel, Ray Benson, and other Texas musicians yet to be announced.

View the Indiegogo campaign at http://www.indiegogo.com/projects/arc-organ-transplantation-solution/x/3662443. Follow it on Twitter: http://www.twitter.com/anyorgananybody and Facebook: http://www.facebook.com/AnyOrganAnyBody.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, L.L.C. (“PTS”) was founded in 2003 by Dr. William Hildebrand, Presbyterian Health Foundation Endowed Professor and the Robert Glenn Rapp Foundation Presidential Professor in the Department of Microbiology and Immunology at The University of Oklahoma Health Sciences Center. Dr. Hildebrand and his team have created a game-changing immunotherapeutic combination medical device for use in a novel selective antibody removal therapy based on thirteen years of expertise in HLA production and application development. This immunotherapeutic device called the HLA-ARCTM (or simply the ARC) is a selective HLA Antibody Removal Column that has the ability to selectively remove only those anti-HLA antibodies that are deleterious to the individual’s transplanted organ or bone marrow. PTS is a subsidiary of Pure Protein L.L.C, a company that has developed and patented several soluble HLA protein technology methods. Visit http://www.pureproteinllc.com for more information.

Cameron Mackie, Emergent Technologies, Inc., 512 263 3232, [email protected]

Modal title

The Selective Antibody Removal Column
The Selective Antibody Removal Column
The Selective Antibody Removal Column

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.